Reduction of quaternary ammonium-induced ocular surface toxicity by emulsions: An in vivo study in rabbits

Molecular Vision

Volumn 14, Issue , 2008, Pages 204-216

  Liang, H ^a,b,c,e   Brignole Baudouin, F ^a,b   Rabinovich Guilatt, L ^d   Mao, Z ^a   Riancho, L ^a   Faure, M O ^d   Warnet, J M ^a   Lambert, G ^d   Baudouin, Christopher ^b,c,e  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b INSERM   (France)

^c CENTRE HOSPITALIER NATIONAL D OPHTALMOLOGIE DES QUINZE VINGTS   (France)

^d Novagali Pharma   (France)

^e LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BENZALKONIUM CHLORIDE; CD45 ANTIGEN; CETALKONIUM HALIDE; DNA NUCLEOTIDYLEXOTRANSFERASE; DRUG VEHICLE; EYE DROPS; HLA DR ANTIGEN; PHOSPHATE; QUATERNARY AMMONIUM DERIVATIVE; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL INFILTRATION; CONCENTRATION (PARAMETERS); CONFOCAL MICROSCOPY; CONJUNCTIVITIS; CONTROLLED STUDY; CORNEA EPITHELIUM; CORNEA LIMBUS; EMULSION; EX VIVO STUDY; EYE TOXICITY; FLOW CYTOMETRY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IMPRESSION CYTOLOGY; IN VIVO STUDY; INFLAMMATORY CELL; KERATITIS; MALE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SLIT LAMP; TOXIN ANALYSIS;

ANIMALS; ANTIGENS, CD45; BENZALKONIUM COMPOUNDS; CONJUNCTIVA; CRYOULTRAMICROTOMY; EMULSIONS; EYE; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; INSTILLATION, DRUG; MALE; MICROSCOPY, CONFOCAL; OXAZINES; QUATERNARY AMMONIUM COMPOUNDS; RABBITS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SURFACE PROPERTIES;

EID: 38949172038     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Tamilvanan S. Oil-in-water lipid emulsions: implications for parenteral and ocular delivering systems. Prog Lipid Res 2004; 43:489-533.
2. Tamilvanan S, Benita S. The potential of lipid-emulsion for ocular delivery of lipophilic drugs. Eur J Pharm Biopharm 2004; 58:357-68.
3. Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group. Ophthalmology 2000; 107:967-74.
4. Lambert G. Preclinical development of a new cyclosporine A eye drop emulsion. Proceedings of the 9th International Congress of International Ocular Inflammation Society; 2007 Sep 17-20; Paris, France.
5. Gershanik T, Benzeno S, Benita S., Interaction of a self-emulsifying lipid drug delivery system with the everted rat intestinal mucosa as a function of droplet size and surface charge. Pharm Res 1998; 15:863-9.
6. Reck RA. Quaternary ammonium compounds. In: Mark HF, Othmer DF, Overberger CG, Seaborg GT, editors. Encyclopedia of Chemical Technology. Toronto: John Wiley & Sons; 1982. p. 521-531.
7. Rolando M, Brezzo G, Giordano P, Campagna P, Burlando S, Calabria G. The effect of different benzalkonium chloride concentrations on human normal ocular surface: a controlled prospective impression cytology study. In: Van Bijsterweld OP, Lemp MA, Spinelli D, editors, The Lacrimal System. Amsterdam: Kagler & Ghedini; 1991. p. 89-91.
8. Debbasch C, Pisella PJ, De Saint Jean M, Rat P, Warnet JM, Baudouin C. Mitochondrial activity and glutathione injury in apoptosis induced by unpreserved and preserved beta-blockers on Chang conjunctival cells. Invest Ophthalmol Vis Sci 2001; 42:2525-33.
9. De Saint Jean M, Brignole F, Bringuier AF, Bauchet A, Feldmann G, Baudouin C. Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells. Invest Ophthalmol Vis Sci 1999; 40:619-30.
10. Debbasch C, Brignole F, Pisella PJ, Warnet JM, Rat P, Baudouin C. Quaternary ammoniums and other preservatives' contribution in oxidative stress and apoptosis on Chang conjunctival cells. Invest Ophthalmol Vis Sci 2001; 42:642-52.
11. Guenoun JM, Baudouin C, Rat P, Pauly A, Warnet JM, Brignole-Baudouin F. In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells. Invest Ophthalmol Vis Sci 2005; 46:2444-50.
12. Guenoun JM, Baudouin C, Rat P, Pauly A, Warnet JM, Brignole-Baudouin F. In vitro comparison of cytoprotective and antioxidative effects of latanoprost, travoprost, and bimatoprost on conjunctiva-derived epithelial cells. Invest Ophthalmol. Vis Sci 2005; 46:4594-9.
13. Chung SH, Lee SK, Cristol SM, Lee ES, Lee DW, Seo KY, Kim EK. Impact of short-term exposure of commercial eyedrops preserved with benzalkonium-chloride on precorneal mucin. Mol Vis 2006; 12:45-21.
14. Baudouin C, Hamard P, Liang H, Creuzot-Garcher C, Bensoussan L, Brignole F. Conjunctival epithelial cell expression of interleukins and inflammatory markers in glaucoma patients treated over the long term. Ophthalmology 2004; 111:2186-92.
15. Baudouin C, Liang H, Bremond-Gignac D, Hamard P, Hreiche R, Creuzot-Garcher C, Warnet JM, Brignole-Baudouin F. CCR 4 and CCR 5 expression in conjunctival specimens as differential markers of T(H)1/ T(H)2 in ocular surface disorders. J Allergy Clin Immunol 2005; 116:614-9.
16. Baudouin C, Liang H, Hamard P, Riancho L, Creuzot-Garcher C, Warnet JM, Brignole-Baudouin F. The Ocular Surface of Glaucoma Patients Treated over the Long Term Expresses Inflammatory Markers Related to Both T-Helper 1 and T-Helper 2 Pathways. Ophthalmology 2008; 115109-15.
17. Broadway DC, Grierson I, O'Brien C, Hitchings RA. Adverse effects of topical antiglaucoma meditation. II. The outcome of filtration surgery. Arch Ophthalmol 1994; 112:1446-54.
18. Sila-On W, Vardhanabhuti N, Ongpipattanakul B, Kulvanich P. The influence of physicochemical properties of preservative compounds on their distribution into various phases of oil in water submicron emulsion. PDA J Pharm Sci Technol 2006; 60:172-81.
19. Kazmi. SJ, Mitchell AG. Preservation oe solubilized and emulsified systems I: Correlation of mathematically predicted preservative availability with antimicrobial activity. J Pharm Sci 1978; 67:1260-6.
20. Kazmi SJ, Mitchell AG. Preservation of solubilizea and emulsified systems II: Theoretical development of capacity and its role in antimicrobial activity of chlorocresol in cetomacrogol-stabilized systems. J Pharm Sci 1978; 67:1266-71.
21. Han J, Washington C. Partition of antimicrobial additives in an intravenous emulsion and their effect on emulsion physical stability. Int J Pharm 2005; 288:263-71.
22. Sznitowska M, Janicki S, Dabrowska, EA, Gajewska M. Physicochemical screening of antimicrobial agents as potential preservatives for submicron emulsions. Eur J Pharm Sci 2002; 15:489-95.
23. Herman JR, Bass P. Enteric neuronal ablation: structure-activity relationship in a series of alkyldimethylbenzylammonium chlorides. Fundam Appl Toxicol 1989, 13:576-84.
24. Smith MJ, Flowers TH, Cowling MJ, Duncan HJ. Method for the measurement of the diffusion coefficient of benzalkonium chloride. Water Res 2002; 36:1423-8.
25. Liang H, Brignole-Baudouin F, Labbe A, Pauly A, Warriet JM, Baudouin C. LPS-stimulated inflammation and apoptosis in corneal injury models. Mol Vis 2007; 11: 1169-80.
26. Liang H, Baudouin C, Labbe A, Pauly A, Martin C, Warnet JM, Brignole-Baudouin F. In vivo confocal microscopy and ex vivo flow cytometry: new tools for assessing ocular inflammation applied to rabbit lipopolysaccharide-induced conjunctivitis. Mol Vis 2006; 12:1392-402.
27. Labbe A, Pauly A, Liang H, Brignole-Baudouin F, Martin C, Warnet JM, Baudouin.C. Comparison of toxicological profiles of benzalkonium chloride and polyquaternium-1: an experimental study. J Ocul Phanmcol Ther 2006; 22:267-78.
28. Pauly A, Brignole-Baudouin F, Labbe A, Liang H, Warnet JM, Baudouin C. New tools for the evaluation of toxic ocular surface changes in the rat. Invest Ophthalmol Vis Sci 2007; 48:5473-83.
29. Ichijima H, Petroll WM, Jester JV, Cavanagh HD. Confocal microscopic studies of living rabbit cornea treated with benzalkonium chloride. Cornea 1992; 11:221-5.
30. Nelson JD. Impression cytology. Cornea 1988; 7:71-81.
31. Cohen T, Sauvageon-Martre H, Brossard D, D'Hermies F, Bardin C, Chast F, Chaumeil JC. Amphotericin B eye drops as a lipidic emulsion. Int J Pharm 1996; 137:249-54.
32. Barber LD, Pflugfelder SC, Tauber J, Foulks GN. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Ophthalmology 2005; 112:1790-4.
33. Di Pascuale MA, Goto E, Tseng SC. Sequential changes of lipid tear film after the instillation of a single drop of a new emulsion eye drop in dry eye patients. Ophthalmology 2004; 111:783-91.
34. Lambert G, Rabinovich-Guilatt L. Cationic oil-in-water emulsion as an improved cyclosporine ocular vehicle for vernal keratoconjuctivitis sicca (VKC). ARVO Annual Meeting; 2007 May 6-10; Fort Lauderdale (FL).
35. Klang S, Abdulrazik M, Benita S. Influence of emulsion droplet surface charge on indomethacin ocular tissue distribution. Pharm Dev Technol 2000; 5:521-32,
36. Abdulrazik M, Tamilvanan S, Khoury K, Benita S. Ocular delivery of cyclosporin A. H. Effect of submicron emulsion's surface charge on ocular distribution of topical cyclosporin A. STP Pharma Sci 2001; 11:427-32.
37. Rabinovich-Guilatt L, Abdulrazik M, Benita S, Lambert G. Cationic emulsions as innovative treatments for dry eye. Proceedings of the 6th International Symposium on Ocular Pharmacology and Therapeutics; 2006 March 30-April 2; Berlin, Germany.
38. Furrer P, Plazonnet B, Mayer JM, Gurny R. Application of in vivo confocal microscopy to the objective evaluation of ocular irritation induced by surfactants. Int J Pharm, 2000; 207:89-98.
39. Pisella PJ, Debbasch C, Hamard P, Creuzot-Garcher C, Rat P, Brignole F, Baudouin C. Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest Ophthalmol Vis Sci 2004; 45:1360-8.
40. Jaenen N, Baudouin C, Pouliquen P, Manni G, Figueiredo A, Zeyen T. Ocular symptom and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol. 2007; 17:341-9.
41. Mietz H, Niesen U, Krieglstein GK. The effect of preservatives and antiglaucomatous medication on the histopathology of the conjunctiva. Graefes Arch Clin Exp Ophthalmol 1994; 232:561-5.
42. Schwab IR, Linberg JV, Gioia VM, Benson WH, Chao GM. Foreshortening of the inferior conjunctival fornix associated with chronic glaucoma medications. Ophthalmology 1992; 99:197-202.
43. McDonnell G, Russell AD. Antiseptics and disinfectants: activity, action and resistance. Clin Microbiol Rev 1999; 12:147-79.
44. Marcotte L, Barbeau J, Lafleur M. Permeability and thermodynamics study of quaternary ammonium surfactants-phosphocholine vesicle system. J Colloid Interface Sci 2005; 292:219-27.
45. Brignole-Baudouin F, Ott AC, Warnet JM, Baudouin C. Flow cytometry in conjunctival impression cytology: a new tool for exploring ocular surface pathologies. Exp Eye Res 2004; 78:473-81.